Maj S. Madsen-Orum

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.

Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.

Journal: Nature communications
Published: October 09, 2023

Malaria Biomimetic for Tumor Targeted Drug Delivery.

Malaria Biomimetic for Tumor Targeted Drug Delivery.

Journal: ACS nano
Published: July 12, 2023

Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.

Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.

Journal: Cancer discovery
Published: November 21, 2020

Development of a bispecific immune engager using a recombinant malaria protein.

Development of a bispecific immune engager using a recombinant malaria protein.

Journal: Cell death & disease
Published: August 24, 2020

A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.

A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.

Journal: Cell death discovery
Published: June 09, 2020

Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors.

Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors.

Journal: Cells
Published: February 10, 2020

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Journal: European urology
Published: September 09, 2016

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Journal: Oncotarget
Published: April 14, 2016

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Journal: Molecular cancer research : MCR
Published: April 06, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026